Fulvestrant, a new treatment option for advanced breast cancer: Tolerability versus existing agents

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 200-204

  Vergote, Ignace ^a   Abram, P ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Breast; Breast cancer; Fulvestrant; Hormone; Neoplasms; Therapy

Indexed keywords

ALKALINE PHOSPHATASE; ANASTROZOLE; AROMATASE INHIBITOR; BILIRUBIN; ESTROGEN; EXEMESTANE; FORMESTANE; FULVESTRANT; GAMMA GLUTAMYLTRANSFERASE; HORMONE RECEPTOR; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN;

ACNE; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ASTHENIA; BILIRUBIN BLOOD LEVEL; BODY WEIGHT DISORDER; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER RISK; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GLUTEUS MAXIMUS MUSCLE; HEADACHE; HIGH RISK PATIENT; HOARSENESS; HOT FLUSH; HUMAN; HYPERTRICHOSIS; HYPOTENSION; INJECTION SITE ABSCESS; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE MASS; INJECTION SITE PAIN; LIVER TOXICITY; LONG TERM CARE; MYALGIA; NEUROTOXICITY; OPEN STUDY; OSTEOARTHRITIS; PARALLEL DESIGN; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN TOXICITY; THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINA DISCHARGE; VAGINITIS; WEIGHT GAIN;

EID: 31544445306     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj047     Document Type: Review

References (30)

1. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3873.
2. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87: 1354-1359.
3. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
4. Howell A, Robertson JFR, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
5. Mauriac L, Pippen JE, Quaresma Albano J et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003; 39: 1228-1233.
6. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-238.
7. Pippen J, Osborne CK, Howell A, Robertson JFR. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: A prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat 2003; 82 (Suppl 1): S101 (Abstr 426).
8. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res 1986; 46: 4823-4826.
9. Howell A, Robertson JFR, Abram P et al. Comparison of fulvestrant v tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
11. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
12. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001; 19: 2596-2606.
13. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-537.
14. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
15. Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006-2016.
16. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461.
17. Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
18. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398.
19. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast group. Proc Am Soc Clin Oncol 2004; 23: 6 (Abstr 515).
20. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996; 14: 2000-2011.
21. Wiseman LR, Adkins JC. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998; 13: 321-332.
22. Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998; 56: 1125-1140.
23. Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39: 2318-2327.
24. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs 2000; 11: 609-616.
25. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999; 21: 297-309.
26. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-1411.
27. Thurlimann B, Paridaens R, Serin D et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997; 33: 1767-1773.
28. Jones S, Vogel C, Arkhipov A et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999; 17: 3418-3425.
29. Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356: 881-887.
30. Fallowfield L, Atkins L, Catt S et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 2005; doi:10.1093/ annonc/mdj044.